Abstract
The addition of chemotherapy to radiotherapy improves survival in LAHNC at the expense of higher toxicity. IMRT for LAHNC provides a means to minimize dose to normal tissue. Our experience with concurrent IMRT and taxane-based chemotherapy in 128 sequential LAHNC patients is presented.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have